SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Invitae tests for both the SMN1 and SMN2 genes in its new test for spinal muscular atrophy, combining diagnostic and prognostic information. () Invitae boosted its genetic testing menu with a new test ...

Invitae is scaling up counseling services after recently signing a contract with Cigna to bring its tests in-network, completing the company’s collection of major commercial health plans and accessing ...

Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price ...

San Francisco-based genetic testing company Invitae has rolled out a one-price-fits-all payment model for its range of tests, charging a set $475 for any test for patients who don’t go through their ...

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to ...